Generic Name and Formulations:
Sacrosidase 8500 IU/mL; oral soln.
QOL Medical, LLC
Indications for SUCRAID:
Oral replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency.
<5months: not recommended. ≥5months: ≤15kg: 8500 IU per meal or snack. >15kg: 17000 IU per meal or snack. Dilute dose with 2–4 ounces of water, milk, or infant formula. Serve cold or at room temp; do not warm up or heat liquid before or after addition of Sucraid. Give half the dose at the beginning of the meal/snack and the remainder during meal/snack.
Hypersensitivity to yeast, glycerin, papain.
Administer initial dose near facility where acute hypersensitivity reactions can be treated; discontinue if hypersensitivity occurs. Diabetes. Evaluate for dietary starch restriction. Secondary disaccharidase deficiencies. Pregnancy (Cat. C).
Do not reconstitute or consume with fruit juice; acidity reduces enzyme activity.
Abdominal pain, GI upset, constipation, insomnia, headache, nervousness, dehydration; rare: wheezing.
Soln (118mL)—2 bottles (w. measuring scoops)
Endocrinology Advisor Articles
- Clinicians May Be Overtreating Older Patients With Diabetes
- Obesity Risk in Infants Born to Women With Diabetes
- Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers
- Prediabetes a Useful Indicator for Cardiovascular and Renal Risks
- Autism Does Not Affect Metabolic Control in Type 1 Diabetes
- Gut Microbiota Profiles in Prediabetes
- Metabolic Syndrome Associated With Higher ALT Levels in Chronic Hepatitis B
- Young Adults With Type 1 Diabetes Show Muscle Metabolic Deficiencies
- Social Support of Autonomy Tied to Better Glycemic Control in Diabetes
- Diabetes May Decrease Ability to Feel Acid Regurgitation